US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Actuate Therapeutics Inc

2.27

-0.0500-2.16%

Post-market: 2.24-0.0300-1.32%19:52 EDT

Volume:43.33K

Turnover:99.99K

Market Cap:52.76M

PE:-1.88

High:2.39

Open:2.31

Low:2.25

Close:2.32

52wk High:11.99

52wk Low:2.15

Shares:23.24M

Float Shares:9.28M

Volume Ratio:0.44

T/O Rate:0.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2044

EPS(LYR):-3.2588

ROE:-296.04%

ROA:-95.25%

PB:4.82

PE(LYR):-0.70

Loading ...

Overview Company News Filings

Actuate Therapeutics FY2025 operating loss narrows 10.59% to $(22.5) million; net loss narrows 18.53% to $(22.2) million

What would a gas tax mean for ASX energy stocks?

Thousands of workers could be in for a pay rise as unions push for wage liftThe push centres on award-reliant workers, who make up the bottom 23 per cent of earners in Australia.2 min read

Actuate Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Actuate launches research initiative to combine elraglusib, RAS inhibitors

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib With Ras Inhibitors

THOMSON REUTERS

Actuate Therapeutics Inc - Initial Data From Program Expected in Q2 2026

THOMSON REUTERS

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Actuate Therapeutics to Present at The Citizens Life Sciences Conference

Millions of Aussies could soon get an extra week of annual leaveThe change to leave entitlements would be the biggest in half a century.3 min read

Actuate Therapeutics CEO Dan Schmitt to present at Oppenheimer Annual Healthcare Life Sciences Conference

Actuate Therapeutics announces plans to expand clinical pipeline

BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers

Actuate Therapeutics Reports Promising Elraglusib Results in Refractory Melanoma

Actuate Therapeutics Inc: Initiation of Phase 1 Portion of Trial Planned in 2H 2026

THOMSON REUTERS

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet Into a Phase 1/2 Clinical Program in Refractory Cancers

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Teva Pharmaceutical (TEVA)

Actuate Therapeutics reports positive Phase 2 pancreatic cancer data

BRIEF-Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing

Actuate Therapeutics says Phase 2 study met primary endpoints

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACTU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":2.27,"timestamp":1774555200000,"preClose":2.32,"halted":0,"volume":43332,"hourTrading":{"tag":"盘后","latestPrice":2.24,"preClose":2.27,"latestTime":"19:52 EDT","volume":539,"amount":1214.412,"timestamp":1774569160050,"change":-0.03,"changeRate":-0.013216,"amplitude":0.01326},"delay":0,"changeRate":-0.02155172413793096,"floatShares":9280300,"shares":23243328,"eps":-1.204351,"marketStatus":"Closed","change":-0.05,"latestTime":"03-26 16:00:00 EDT","open":2.31,"high":2.3853,"low":2.25,"amount":99993.6251784,"amplitude":0.058319,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.204351,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774598400000},"marketStatusCode":5,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":2.32,"postHourTrading":{"tag":"盘后","latestPrice":2.24,"preClose":2.27,"latestTime":"19:52 EDT","volume":539,"amount":1214.412,"timestamp":1774569160050,"change":-0.03,"changeRate":-0.013216,"amplitude":0.01326},"volumeRatio":0.439236},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":9280300,"roa":"-95.25%","roe":"-296.04%","lyrEps":-3.258828,"volumeRatio":0.439236,"shares":23243328,"dividePrice":0,"high":2.3853,"amplitude":0.058319,"preClose":2.32,"low":2.25,"week52Low":2.15,"pbRate":"4.82","week52High":11.99,"institutionHeld":0,"latestPrice":2.27,"eps":-1.204351,"divideRate":0,"volume":43332,"delay":0,"ttmEps":-1.204351,"open":2.31,"prevYearClose":6.12,"prevWeekClose":2.35,"prevMonthClose":3.74,"prevQuarterClose":6.12,"fiveDayClose":2.5,"twentyDayClose":3.95,"sixtyDayClose":5.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"ACTU","fiscalQuarterEnding":"2025/09","expectedEps":-0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-08-14","symbol":"ACTU","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.3},{"market":"US","date":"2025-05-15","symbol":"ACTU","fiscalQuarterEnding":"2025/03","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1756180800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2026-03-25","current":-1.884833,"percent":1,"low":-9.225925,"twenty":-6.610668,"median":-5.760243,"eighty":-4.881955,"high":-2.129676,"avg":-5.734156,"sd":1.120077,"marketCap":51367754},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-13","current":-6.675228,"twenty":-6.406672,"median":-5.69465,"eighty":-5.089546,"marketCap":168925272},{"date":"2025-06-20","current":-5.806906,"twenty":-6.42894,"median":-5.722554,"eighty":-5.141086,"marketCap":146951253},{"date":"2025-06-27","current":-4.512175,"twenty":-6.410449,"median":-5.697878,"eighty":-5.08284,"marketCap":114186421},{"date":"2025-07-03","current":-5.109147,"twenty":-6.389172,"median":-5.691014,"eighty":-5.046525,"marketCap":129293559},{"date":"2025-07-11","current":-4.791279,"twenty":-6.365148,"median":-5.677284,"eighty":-5.035608,"marketCap":121249498},{"date":"2025-07-18","current":-4.853302,"twenty":-6.320988,"median":-5.645656,"eighty":-4.991444,"marketCap":122819071},{"date":"2025-07-25","current":-5.419262,"twenty":-6.287654,"median":-5.638088,"eighty":-4.976956,"marketCap":137141423},{"date":"2025-08-01","current":-5.620836,"twenty":-6.265937,"median":-5.628589,"eighty":-4.986182,"marketCap":142242535},{"date":"2025-08-08","current":-6.527901,"twenty":-6.287654,"median":-5.632466,"eighty":-4.991444,"marketCap":165196967},{"date":"2025-08-15","current":-6.908485,"twenty":-6.414227,"median":-5.639808,"eighty":-4.995735,"marketCap":170525437},{"date":"2025-08-22","current":-6.442036,"twenty":-6.458702,"median":-5.650353,"eighty":-5.00125,"marketCap":159011858},{"date":"2025-08-29","current":-6.908485,"twenty":-6.483225,"median":-5.670419,"eighty":-5.019908,"marketCap":170525437},{"date":"2025-09-05","current":-7.328709,"twenty":-6.512404,"median":-5.690843,"eighty":-5.033989,"marketCap":180898030},{"date":"2025-09-12","current":-5.859066,"twenty":-6.574176,"median":-5.69465,"eighty":-5.040292,"marketCap":144622132},{"date":"2025-09-19","current":-6.375067,"twenty":-6.549229,"median":-5.726634,"eighty":-5.04517,"marketCap":157358843},{"date":"2025-09-26","current":-6.175411,"twenty":-6.549229,"median":-5.729418,"eighty":-5.051947,"marketCap":152430635},{"date":"2025-10-03","current":-6.212557,"twenty":-6.533707,"median":-5.754096,"eighty":-5.069427,"marketCap":153347511},{"date":"2025-10-10","current":-7.512643,"twenty":-6.537578,"median":-5.770478,"eighty":-5.097386,"marketCap":185438171},{"date":"2025-10-17","current":-7.24334,"twenty":-6.589924,"median":-5.79172,"eighty":-5.109147,"marketCap":178790820},{"date":"2025-10-24","current":-6.732591,"twenty":-6.670885,"median":-5.814177,"eighty":-5.112248,"marketCap":166183775},{"date":"2025-10-31","current":-6.110407,"twenty":-6.6744,"median":-5.859066,"eighty":-5.12,"marketCap":150826102},{"date":"2025-11-07","current":-5.785385,"twenty":-6.670885,"median":-5.869501,"eighty":-5.13638,"marketCap":142803437},{"date":"2025-11-14","current":-5.536933,"twenty":-6.66337,"median":-5.85039,"eighty":-5.154603,"marketCap":136670768},{"date":"2025-11-21","current":-5.868654,"twenty":-6.637844,"median":-5.836285,"eighty":-5.160645,"marketCap":141551867},{"date":"2025-11-28","current":-7.352682,"twenty":-6.647528,"median":-5.86386,"eighty":-5.168486,"marketCap":177346592},{"date":"2025-12-05","current":-7.082858,"twenty":-6.676544,"median":-5.869501,"eighty":-5.172026,"marketCap":170838460},{"date":"2025-12-12","current":-7.150314,"twenty":-6.706669,"median":-5.884194,"eighty":-5.183365,"marketCap":172465493},{"date":"2025-12-19","current":-6.764853,"twenty":-6.718803,"median":-5.896423,"eighty":-5.185781,"marketCap":163168162},{"date":"2025-12-26","current":-6.321572,"twenty":-6.721745,"median":-5.917556,"eighty":-5.189762,"marketCap":152476231},{"date":"2026-01-02","current":-5.897564,"twenty":-6.709975,"median":-5.917556,"eighty":-5.218313,"marketCap":142249167},{"date":"2026-01-09","current":-6.051748,"twenty":-6.706828,"median":-5.918043,"eighty":-5.231645,"marketCap":145968099},{"date":"2026-01-16","current":-5.12664,"twenty":-6.706347,"median":-5.916837,"eighty":-5.218313,"marketCap":123654504},{"date":"2026-01-23","current":-5.251915,"twenty":-6.701519,"median":-5.896423,"eighty":-5.230096,"marketCap":126676137},{"date":"2026-01-30","current":-4.567721,"twenty":-6.691045,"median":-5.884194,"eighty":-5.187481,"marketCap":110173374},{"date":"2026-02-06","current":-4.162986,"twenty":-6.680588,"median":-5.869501,"eighty":-5.163192,"marketCap":100411176},{"date":"2026-02-13","current":-4.085894,"twenty":-6.675886,"median":-5.86386,"eighty":-5.121593,"marketCap":98551710},{"date":"2026-02-20","current":-4.085894,"twenty":-6.6744,"median":-5.836285,"eighty":-5.109147,"marketCap":98551710},{"date":"2026-02-27","current":-3.806434,"twenty":-6.670885,"median":-5.810835,"eighty":-5.051947,"marketCap":91811145},{"date":"2026-03-06","current":-3.083693,"twenty":-6.66337,"median":-5.801368,"eighty":-5.014488,"marketCap":74378649},{"date":"2026-03-13","current":-2.457318,"twenty":-6.638594,"median":-5.7914,"eighty":-4.984609,"marketCap":59270486},{"date":"2026-03-20","current":-2.409136,"twenty":-6.610668,"median":-5.770478,"eighty":-4.925104,"marketCap":58108320},{"date":"2026-03-25","current":-2.129676,"twenty":-6.610668,"median":-5.760243,"eighty":-4.881955,"marketCap":51367754}],"updateTime":1774559590279},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622896572","title":"Actuate Therapeutics FY2025 operating loss narrows 10.59% to $(22.5) million; net loss narrows 18.53% to $(22.2) million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896572","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896572?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:01","pubTimestamp":1774555298,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics published its annual report on Form 10-K, reporting no product revenue and a net loss of USD 22.2 million.Research and development expense fell 44.89% to USD 10.3 million, driven mainly by lower external clinical trial expenses as the randomized Phase 2 mPDAC trial winds down and by lower CMC costs due to timing of manufacturing and stability studies.General and administrative expense rose 88.2% to USD 12.2 million, primarily reflecting higher non-cash stock-based compensation and higher public-company related costs including professional fees and directors and officers insurance.Net cash used in operating activities decreased 12.07% to USD 19.2 million, while cash and cash equivalents were USD 13.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2XvSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2621848870","title":"What would a gas tax mean for ASX energy stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621848870","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621848870?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:14","pubTimestamp":1774296870,"startTime":"0","endTime":"0","summary":"It appears momentum is growing for a gas and coal tax in Australia amidst the global energy crisis.According to The ABC, Unions, the Greens, crossbenchers and One Nation are among those who want gas profits levied, with pressure mounting on Labor to respond to growing calls to reform the current tax system.Currently, the government collects about $1.5 billion in annual revenue through the Petroleum resource rent tax .Companies only pay PRRT after they've made enough money to cover all their costs. Once a project becomes really profitable, the government takes a share of those extra profits.However, some politicians are now pushing for reforms to the current model.He said Australia should have a flat 25 per cent tax on all gas exports, which was the proposal also put forward by the Australian Council of Trade Unions  last year.They warned that a new gas tax would discourage investment, create uncertainty, and weaken energy security and job growth.For example, companies such as AGL Energ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/24/what-would-a-gas-tax-mean-for-asx-energy-stocks/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/24/what-would-a-gas-tax-mean-for-asx-energy-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","ACTU","BK7136","STO.AU","WDS.AU","BK7507","AGL.AU","BK7142"],"gpt_icon":0},{"id":"2621355680","title":"Thousands of workers could be in for a pay rise as unions push for wage liftThe push centres on award-reliant workers, who make up the bottom 23 per cent of earners in Australia.2 min read","url":"https://stock-news.laohu8.com/highlight/detail?id=2621355680","media":"7NEWS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621355680?lang=en_us&edition=fundamental","pubTime":"2026-03-24 00:00","pubTimestamp":1774281600,"startTime":"0","endTime":"0","summary":"Thousands of Australia’s lowest-paid workers could be in line for a pay rise, as unions ramp up pressure for a 5 per cent increase to the national minimum wage.The Australian Council of Trade Unions (","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"7news_stock","url":"https://7news.com.au/sunrise/push-for-5-per-cent-pay-rise-as-unions-warn-low-paid-workers-are-still-worse-off-c-22038293","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://7news.com.au/sunrise/push-for-5-per-cent-pay-rise-as-unions-warn-low-paid-workers-are-still-worse-off-c-22038293","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"7news_stock","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2618297331","title":"Actuate Therapeutics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618297331","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618297331?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:02","pubTimestamp":1773259343,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc  expected to post a loss of24cents a share - Earnings Preview Actuate Therapeutics Inc ACTU.OQ ACTU.O is expected to  show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL8N3ZZ2VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2618629581","title":"Actuate launches research initiative to combine elraglusib, RAS inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629581","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618629581?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:57","pubTimestamp":1773061055,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced the launch of an expanded research initiative evaluating combinations of its clinical-stage GSK-3beta inhibit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-launches-research-initiative-to-combine-elraglusib-ras-inhibitors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-launches-research-initiative-to-combine-elraglusib-ras-inhibitors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2618183626","title":"Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib With Ras Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2618183626","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618183626?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:45","pubTimestamp":1773060300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUADGJ5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2618162610","title":"Actuate Therapeutics Inc - Initial Data From Program Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618162610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618162610?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:45","pubTimestamp":1773060300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUADGJ5Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2618626050","title":"Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2618626050","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618626050?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:45","pubTimestamp":1773060300,"startTime":"0","endTime":"0","summary":"Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251848/0/en/Actuate-Therapeutics-Launches-Strategic-Research-Initiative-to-Combine-Elraglusib-with-RAS-Inhibitors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2617562549","title":"Actuate Therapeutics to Present at The Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2617562549","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617562549?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:00","pubTimestamp":1772661600,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, March  04, 2026  (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on develo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249771/0/en/Actuate-Therapeutics-to-Present-at-The-Citizens-Life-Sciences-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2616301214","title":"Millions of Aussies could soon get an extra week of annual leaveThe change to leave entitlements would be the biggest in half a century.3 min read","url":"https://stock-news.laohu8.com/highlight/detail?id=2616301214","media":"7NEWS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616301214?lang=en_us&edition=fundamental","pubTime":"2026-03-04 00:00","pubTimestamp":1772553600,"startTime":"0","endTime":"0","summary":"Australian unions have launched a major push to lift the minimum annual leave entitlement from four to five weeks, marking what would be the first increase to the standard in half a century.The bid, l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"7news_stock","url":"https://7news.com.au/sunrise/unions-push-for-five-weeks-annual-leave-for-australian-workers-to-offset-unpaid-overtime-c-21827564","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://7news.com.au/sunrise/unions-push-for-five-weeks-annual-leave-for-australian-workers-to-offset-unpaid-overtime-c-21827564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"7news_stock","symbols":["BK4139","XJO.AU","ACTU","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2613712991","title":"Actuate Therapeutics CEO Dan Schmitt to present at Oppenheimer Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712991","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712991?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:45","pubTimestamp":1771940736,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics CEO Dan Schmitt to present at Oppenheimer Annual Healthcare Life Sciences Conference               Actuate Therapeutics Inc. (NASDAQ: ACTU) said President and CEO Dan Schmitt will","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL8Qqp7l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","SG9999014039.USD","LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD","BK4139","LU2210149790.SGD","SG9999014005.SGD","BK4588","BK4112","NDAQ","IE00BKPKM429.USD","BK4585","SG9999014013.SGD"],"gpt_icon":0},{"id":"2605100062","title":"Actuate Therapeutics announces plans to expand clinical pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2605100062","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605100062?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:56","pubTimestamp":1769003766,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-plans-to-expand-clinical-pipeline-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-plans-to-expand-clinical-pipeline-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2605100988","title":"BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2605100988","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605100988?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:46","pubTimestamp":1769003184,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory CancersJan 21 (Reuters) - Actuate Therapeutics Inc A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2605100983","title":"Actuate Therapeutics Reports Promising Elraglusib Results in Refractory Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2605100983","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605100983?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:45","pubTimestamp":1769003117,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc. has announced plans to advance its elraglusib oral tablet into a Phase 1/2 clinical program targeting refractory cancers, including metastatic melanoma. The program builds on encouraging early clinical evidence of monotherapy activity from a previously completed trial using the IV formulation of elraglusib, which included a complete response lasting over six years in a patient with advanced, refractory BRAFV600E-mutated metastatic melanoma. The upcoming Phase 1 portion, scheduled to begin in the second half of 2026, will assess safety, dosing, and preliminary anti-tumor activity of the oral tablet. The results referenced were from prior studies, and the new research will be conducted and presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL9s2dPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","ACTU","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","BK4588","BK4112","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","BK4139","SG9999014039.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2605100626","title":"Actuate Therapeutics Inc: Initiation of Phase 1 Portion of Trial Planned in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605100626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605100626?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:45","pubTimestamp":1769003107,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0NI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2605006251","title":"Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet Into a Phase 1/2 Clinical Program in Refractory Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2605006251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605006251?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:45","pubTimestamp":1769003107,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2603360244","title":"Analysts Are Bullish on Top Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Teva Pharmaceutical (TEVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603360244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603360244?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:11","pubTimestamp":1768479066,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actuate Therapeutics, Inc. (ACTU – Research Report) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-actuate-therapeutics-inc-actu-teva-pharmaceutical-teva-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-actuate-therapeutics-inc-actu-teva-pharmaceutical-teva-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4137","BK4588","LU0029874061.USD","BK4557","BK4007","BK4112","BK4566","BK4559","LU1983299246.USD","LABU","XBI","BK4585","BK4596","TEVA","BK4581","LU0128526141.USD","BK4584","BK4139"],"gpt_icon":0},{"id":"2603356529","title":"Actuate Therapeutics reports positive Phase 2 pancreatic cancer data","url":"https://stock-news.laohu8.com/highlight/detail?id=2603356529","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603356529?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:39","pubTimestamp":1768253996,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Actuate Therapeutics, Inc. ( ($ACTU) ). On January 12, 2026, Actuate Therapeutics reported positive follow-up d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-reports-positive-phase-2-pancreatic-cancer-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-reports-positive-phase-2-pancreatic-cancer-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2603526582","title":"BRIEF-Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526582","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526582?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:06","pubTimestamp":1768251985,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC FilingJan 12  - SEC Filing:ACTUATE THERAPEUTICS INC - REPORTS POSITIVE PHASE 2 TRIAL DATA FOR ELRAGLUSIB - SEC FILINGACTUATE THERAPEUTICS INC - PHASE 2 STUDY SHOWS IMPROVED SURVIVAL WITH ELRAGLUSIB - SEC FILINGSource text: [ID:n0001683168-26-000217]Further company coverage: ACTU.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0RP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2602114543","title":"Actuate Therapeutics says Phase 2 study met primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2602114543","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602114543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:51","pubTimestamp":1768225887,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced that new additional and promising patient survival and biomarker data from treatment with elraglusib for meta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-says-phase-2-study-met-primary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-says-phase-2-study-met-primary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0004445015.USD","LU1868836914.USD","IE00BMPRXQ63.HKD","LU2458330169.SGD","LU0882574139.USD","LU2065171311.SGD","LU1861559042.SGD","LU1429558221.USD","LU1074936037.SGD","HK0000914686.HKD","LU2125154935.USD","LU1629891620.HKD","LU0079474960.USD","LU0256863902.USD","IE00BN29S564.USD","LU0912757837.SGD","LU0170899867.USD","IE0009G5SDU7.USD","LU1145028129.USD","LU2247934214.USD","LU2168564149.EUR","LU1778281490.HKD","LU2361044865.SGD","LU0784385170.HKD","LU0323591593.USD","IE00BWXC8680.SGD","SGXZ99366536.SGD","SG9999018865.SGD","IE0034235188.USD","LU0648001328.SGD","LU1670711123.USD","LU0265550359.USD","LU0096364046.USD","IE0034235303.USD","LU1366333091.USD","LU1366192091.USD","LU0708995401.HKD","LU2462157665.USD","LU2265009873.SGD","LU0225283273.USD","LU0957808578.USD","LU0198837287.USD","IE00B19Z9505.USD","LU1564329032.USD","LU1992135472.HKD","LU2097829019.USD","LU1551013425.SGD","LU2213496289.HKD","LU0320765489.SGD","LU0203202063.USD","LU0553294199.USD","LU2764262908.HKD","LU2430703095.HKD","BK4524","LU2552382058.USD","LU1814569148.SGD","IE00B3SWFQ91.USD","IE00B4YYXB79.USD","LU0787776722.HKD","IE0004445239.USD","LU1564329461.SGD","LU2322448791.USD","IE00BJTD4N35.SGD","BK4077","LU1201861249.SGD","LU0109392836.USD","SG9999017495.SGD","LU2063271972.USD","LU2023250843.SGD","LU0308772762.SGD","LU2720916845.USD","LU0823434740.USD","LU0210533765.USD","LU0719512351.SGD","LU0096362180.USD","LU1992135399.USD","LU0210528500.USD","LU1116320737.USD","LU0820561909.HKD","LU0061474705.USD","LU1153585028.USD","LU0889565833.HKD","LU2505996509.AUD","LU0211331839.USD","LU0082616367.USD","LU2458330243.SGD","LU1232071149.USD","LU0690374615.EUR","SG9999015986.USD","LU0215105999.USD","LU2456880835.USD","BK4587","LU0943347566.SGD","SGXZ23171101.USD","LU0068578508.USD","LU0203347892.USD","LU0545039389.USD","LU0070217475.USD","LU2250418816.HKD","SG9999004303.SGD","LU1489326972.SGD","LU1697837992.HKD","LU1988902786.USD","LU1670711040.USD","LU2087625088.SGD","LU2236285917.USD","LU0320765059.SGD","LU1066051498.USD","LU0234572021.USD","LU0878866978.SGD","IE00BKDWB100.SGD","LU1674673428.USD","LU0154236417.USD","LU2357305700.SGD","LU2168564222.USD","LU0724617625.USD","LU1496350502.SGD","LU0348723411.USD","IE000W1ABFV2.USD","IE0009356076.USD","IE00B19Z3B42.SGD","LU0006306889.USD","LU2602419157.SGD","LU1868837136.USD","LU1316542783.SGD","LU2125154778.USD","SG9999002232.USD","LU1670628061.USD","LU2347655156.SGD","LU2054465674.USD","LU2065171402.SGD","LU2505996681.GBP","IE0005OL40V9.USD","LU1119994496.HKD","LU0072462426.USD","LU1242518857.USD","LU0823421416.USD","LU0444971666.USD","GB00B4QBRK32.GBP","LU2133065610.SGD","LU0964807845.USD","LU2592432038.USD","IE00B19Z3581.USD","LU0080751232.USD","IE00BMPRXR70.SGD","IE00B7KXQ091.USD","LU1267930490.SGD","LU1571399168.USD","LU2487616109.SGD","LU1242518931.SGD","LU0353189680.USD","LU1720051017.SGD","LU0061475181.USD","LU2361045086.USD","LU2896262040.SGD","LU0208291251.USD","LU0097036916.USD","LU2023250504.SGD","LU1003077747.HKD","LU0726765562.USD","LU0795875169.SGD","IE00BJLML261.HKD","BK4543","LU0345769631.USD","LU0056508442.USD","LU1261432733.SGD","LU2430703178.SGD","IE000KEQY171.SGD","LU0957791311.USD","IE00BJTD4V19.USD","LU0690374961.EUR","IE00BQXX3D17.EUR","LU2463028550.USD","LU0985320562.USD","LU1564329115.USD","SG9999014880.SGD","LU2237957811.SGD","SGXZ31699556.SGD","LU2168564495.EUR","IE00BFSS7M15.SGD","LU2317271919.USD","LU2326559502.SGD","LU1815336760.USD","SG9999015945.SGD","LU1280957306.USD","LU2404859667.USD","LU2264538146.SGD","LU2756315664.SGD","GB00B4LPDJ14.GBP","LU0211328371.USD","LU0642271901.SGD","LU0949170426.SGD","LU0053666078.USD","LU2420271590.USD","LU0672654240.SGD","LU1699723380.USD","LU0211327993.USD","LU2746668461.USD","LU2361044949.HKD","LU1069344957.HKD","LU0784385840.USD","SG9999015978.USD","LU1035775433.USD","SG9999014914.USD","LU0345769128.USD","LU0157215616.USD","ACTU","LU0106261372.USD","SG9999002224.SGD","LU2404859741.USD","SG9999018857.SGD","LU1235294995.USD","LU0823434583.USD","HK0000914660.USD","LU0077335932.USD","LU2552382215.SGD","IE00B5949003.HKD","SG9999014906.USD","LU1267930730.SGD","LU1974910355.USD","SGXZ81514606.USD","LU1084165304.USD","LU0127658192.USD","LU0683600562.USD","GB00BDT5M118.USD","LU0476273544.USD","BK4585","LU1670710661.SGD","LU0640476718.USD","LU0528227936.USD","LU2087621335.USD","LU0011850046.USD","BK4592","LU0444973449.USD","IE00BJJMRX11.SGD","LU1861558580.USD","LU2272731600.USD","LU1914381329.SGD","LU0256863811.USD","IE00B19Z8X17.USD","LU0795875086.SGD","LU0433182093.SGD","LU2552382132.HKD","IE000ITXATA3.USD","IE00BFSS8Q28.SGD","IE0003U64NQ7.SGD","LU2272731865.HKD","LU1127390331.HKD","IE0001KFT4U8.USD","LU0466842654.USD","LU1791710582.SGD","SG9999014898.SGD","LU0980610538.SGD","LU1732800096.USD","LU1823568750.SGD","LU0310799852.SGD","LU1670627923.USD","LU0267386448.USD","LU0316494557.USD","LU0784384876.USD","LU0738911758.USD","LU2347655073.USD","LU2360032135.SGD","LU0354030438.USD","LU1852331112.SGD","LU1670710588.SGD","LU0276348264.USD","IE00B775H168.HKD","LU0203345920.USD","IE00BQXX3F31.USD","LU0979878070.USD","LU2272731782.SGD","LU2746668974.SGD","LU2764263039.SGD","SGXZ51526630.SGD","IE00B1XK9C88.USD","LU2322448957.HKD","LU0786609619.USD","LU2242650005.HKD","IE00BK4W5M84.HKD","LU2168564065.EUR","LU1868837300.USD","LU2168563687.JPY","LU0210536198.USD","LU0265550946.USD","LU2403377893.USD","LU2065170008.USD","LU2065169927.USD","LU2106854487.HKD","LU1732799900.SGD","LU1804176565.USD","LU0149725797.USD","LU1868836757.USD","LU2430703251.USD","LU1815333072.USD","LU0417517546.SGD","LU1548497426.USD","SG9999015952.SGD","LU0234570918.USD","LU2360106780.USD","LU1046421795.USD","LU0784383803.USD","LU1116320901.HKD","IE00BK4W5L77.USD","LU1718418525.SGD","IE00BMPRXN33.USD","LU0130102774.USD","BK4507","LU1642822529.SGD","LU1868836591.USD","LU1720051108.HKD","LU0788109477.HKD","LU2543165471.USD","LU2417539215.USD","LU2237957902.USD","LU1674673691.USD","LU0070302665.USD","LU1791710400.SGD","LU0061474960.USD","LU0823421333.USD","LU1839511570.USD","IE00B4JS1V06.HKD","IE00BJJMRY28.SGD","IE00B7SZLL34.SGD","LU1064131342.USD","LU0203201768.USD","LU2461242641.AUD","LU1551013342.USD","BK4588","IE00B1BXHZ80.USD","LU1066053197.SGD","LU2381873111.SGD","LU0109391861.USD","IE0002270589.USD","LU0353189763.USD","LU0985489474.SGD","LU2764263203.CNY","LU0689472784.USD","LU0820562030.AUD","LU0949170772.SGD","LU2473716301.USD","LU1301847155.USD","IE000YTNTUN2.SGD","LU2756315318.SGD","LU2860962120.EUR","LU1564329628.SGD","LU2023250330.USD","LU1435385759.SGD","BK4139","LU0820561818.USD","IE00B19Z8W00.USD","LU1803068979.SGD","LU0661504455.SGD","LU1917777945.USD","SG9999001077.SGD","IE00BQXX3C00.GBP","LU0354030511.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}